Cymabay Stock Today


USD 3.42  0.08  2.29%   

Market Performance
5 of 100
Odds Of Distress
Over 91
Cymabay Therapeutics is trading at 3.42 as of the 3rd of October 2022; that is -2.29 percent decrease since the beginning of the trading day. The stock's open price was 3.5. Cymabay Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for Cymabay Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 13th of October 2020 and ending today, the 3rd of October 2022. Click here to learn more.
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California. The company has 84.67 M outstanding shares of which 3.5 M shares are currently shorted by private and institutional investors with about 3.01 trading days to cover. More on Cymabay Therapeutics
Follow Valuation Odds of Bankruptcy
Check how we calculate scores

Cymabay Therapeutics Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Cymabay Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Cymabay Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Cymabay Therapeutics has very high historical volatility over the last 90 days
Cymabay Therapeutics has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 5.21 M. Net Loss for the year was (100.22 M) with loss before overhead, payroll, taxes, and interest of (43.73 M).
Cymabay Therapeutics currently holds about 188.56 M in cash with (74.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.23.
Over 79.0% of the company shares are held by institutions such as insurance companies
Latest headline from CymaBay Therapeutics, Inc. is definitely on the radar of institutional investors who own 50 percent of the company - Nasdaq
CEO and President and DirectorHarold Wart
Thematic IdeaDisruptive Technologies (view all)
Average Analyst Recommendation
Analysts covering Cymabay Therapeutics report their recommendations after researching Cymabay Therapeutics' financial statements, talking to executives and customers, or listening in on Cymabay Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Cymabay Therapeutics. The Cymabay consensus assessment is calculated by taking the average forecast from all of the analysts covering Cymabay Therapeutics.
Strong Buy8 Opinions
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Cymabay Therapeutics' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Cautious HoldUndervalued
Cymabay Therapeutics (CBAY) is traded on NASDAQ Exchange in USA and employs 59 people. The company currently falls under 'Small-Cap' category with current market capitalization of 296.34 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Cymabay Therapeutics's market, we take the total number of its shares issued and multiply it by Cymabay Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Cymabay Therapeutics conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 84.67 M outstanding shares of which 3.5 M shares are currently shorted by private and institutional investors with about 3.01 trading days to cover. Cymabay Therapeutics currently holds about 188.56 M in cash with (74.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.23.
Check Cymabay Therapeutics Probability Of Bankruptcy
Cymabay Therapeutics retains a total of 84.67 Million outstanding shares. The majority of Cymabay Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Cymabay Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Cymabay Therapeutics. Please pay attention to any change in the institutional holdings of Cymabay Therapeutics as this could imply that something significant has changed or about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Ownership Allocation (%)

Check Cymabay Ownership Details

Cymabay Stock Price Odds Analysis

Based on a normal probability distribution, the odds of Cymabay Therapeutics jumping above the current price in 90 days from now is about 66.59%. The Cymabay Therapeutics probability density function shows the probability of Cymabay Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Cymabay Therapeutics has a beta of 0.3932 suggesting as returns on the market go up, Cymabay Therapeutics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Cymabay Therapeutics will be expected to be much smaller as well. Additionally, the company has an alpha of 0.4178, implying that it can generate a 0.42 percent excess return over DOW after adjusting for the inherited market risk (beta).
  Odds Below 3.42HorizonTargetOdds Above 3.42
33.28%90 days
Based on a normal probability distribution, the odds of Cymabay Therapeutics to move above the current price in 90 days from now is about 66.59 (This Cymabay Therapeutics probability density function shows the probability of Cymabay Stock to fall within a particular range of prices over 90 days) .

Cymabay Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Cymabay Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Cymabay Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Cymabay Therapeutics' value.
InstituionSecurity TypeTotal SharesValue
Avoro Capital Advisors LlcCommon Shares10.3 M30.4 M
Tcg Crossover Management LlcCommon Shares5.9 M17.4 M
View Cymabay Therapeutics Diagnostics

Cymabay Therapeutics Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Cymabay Therapeutics market risk premium is the additional return an investor will receive from holding Cymabay Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Cymabay Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Cymabay Therapeutics' alpha and beta are two of the key measurements used to evaluate Cymabay Therapeutics' performance over the market, the standard measures of volatility play an important role as well.

Cymabay Stock Against Markets

Picking the right benchmark for Cymabay Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Cymabay Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Cymabay Therapeutics is critical whether you are bullish or bearish towards Cymabay Therapeutics at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Cymabay Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Options Analysis Now


Options Analysis

Analyze and evaluate options and option chains as a potential hedge for your portfolios
All  Next Launch Module

Cymabay Therapeutics Corporate Directors

Cymabay Therapeutics corporate directors refer to members of a Cymabay Therapeutics board of directors. The board of directors generally takes responsibility for the Cymabay Therapeutics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Cymabay Therapeutics' board members must vote for the resolution. The Cymabay Therapeutics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Kurt Emster - Independent DirectorProfile
Caroline Loewy - DirectorProfile
Robert Weiland - DirectorProfile
Paul Truex - DirectorProfile

Invested in Cymabay Therapeutics?

The danger of trading Cymabay Therapeutics is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Cymabay Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Cymabay Therapeutics. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Cymabay Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Continue to Trending Equities. Note that the Cymabay Therapeutics information on this page should be used as a complementary analysis to other Cymabay Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.

Complementary Tools for Cymabay Stock analysis

When running Cymabay Therapeutics price analysis, check to measure Cymabay Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cymabay Therapeutics is operating at the current time. Most of Cymabay Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cymabay Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Cymabay Therapeutics' price. Additionally, you may evaluate how the addition of Cymabay Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Is Cymabay Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cymabay Therapeutics. If investors know Cymabay will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cymabay Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Cymabay Therapeutics is measured differently than its book value, which is the value of Cymabay that is recorded on the company's balance sheet. Investors also form their own opinion of Cymabay Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cymabay Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cymabay Therapeutics' market value can be influenced by many factors that don't directly affect Cymabay Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cymabay Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Cymabay Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cymabay Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.